Surrey Heartlands

Joint Formulary & PAD

Tamoxifen citrate - Breast cancer

You are here : Home > Formulary Search > Tamoxifen citrate - Breast cancer

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :
Important

1st month supply from specialist team before request for primary care prescribing

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tamoxifen citrate
Indication :
Breast cancer
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Tamoxifen citrate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Breast cancer.

Committee Recommendations (1)

07 Aug 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a formulary status for tamoxifen, anastrozole and raloxifene for chemoprevention in women at moderate or high risk of developing breast cancer for a duration of 5 years.

A BLUE (with specialist initiation) with 1 month prescribing by the specialist team following discussions with the patient about the risks and benefits of treatment.

Tamoxifen can be used:

  • Premenopausal except in those with past history or may be at increased risk of thromboembolic disease or endometrial cancer
  • Postmenopausal who have severe osteoporosis or do not wish to take anastrozole if no past history or increased risk of thromboembolic disease or endometrial cancer

On occasion a patient may need time to consider treatment and may in those circumstances request that their GP prescribe. The GP will then need to consider if they have all the information from the specialist team in order to accept full clinical responsibility for prescribing for that patient.